Clinician Perspectives on Current Issues in Lung Cancer Drug Development.
Waqar, Saiama N. M.B.B.S., MSCI; Bonomi, Philip D. MD; Govindan, Ramaswamy MD; Hirsch, Fred R. MD, PhD; Riely, Gregory J. MD; Papadimitrakopoulou, Vassiliki MD; Kazandjian, Dickran MD; Khozin, Sean MD; Larkins, Erin MD; Dickson, Dane J. MD; Malik, Shakun MD; Horn, Leora MD; Ferris, Andrea MBA; Shaw, Alice T. MD, PhD; Janne, Pasi A. MD, PhD; Mok, Tony S.K. MD; Herbst, Roy MD, PhD; Keegan, Patricia MD; Pazdur, Richard MD; Blumenthal, Gideon M. MD
Journal of Thoracic Oncology.
11(9):1387-1396, September 2016.
(Format: HTML, PDF)
: Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy.
Copyright (C) 2016 by the International Association for the Study of Lung Cancer